Patents by Inventor Agnete Fredriksen

Agnete Fredriksen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Immunogenic Constructs And Vaccines For Use In The Prophylactic And Therapeutic Treatment Of Diseases Caused By SARS-CoV-2
    Publication number: 20250049910
    Abstract: This invention relates to immunogenic constructs, such as polynucleotides, polypeptides and multimeric proteins and to antigenic units and to pharmaceutical compositions/vaccines comprising such immunogenic constructs or antigenic units, which are useful for the prophylactic and therapeutic treatment of diseases caused by severe acute respiratory coronavirus 2 (SARS-CoV-2), as well as methods for producing and using the immunogenic constructs, antigenic units and pharmaceutical compositions/vaccines.
    Type: Application
    Filed: November 3, 2022
    Publication date: February 13, 2025
    Applicants: Nykode Therapeutics ASA, Adaptive Biotechnologies Corporation
    Inventors: Peter Ebert, Agnete Fredriksen, Mark Klinger, Gunnstein Norheim, Edward Osborne, Monika Sekelja, Thomas Snyder, Elisabeth Stubsrud
  • Modified antibody
    Patent number: 8932603
    Abstract: Recombinant antibody-based molecules that trigger both T-cell and B-cell immune responses are disclosed. The recombinant molecules are comprised by at least one targeting unit and at least one antigenic unit connected through a dimerization motif. Also disclosed are nucleic acid molecules encoding the recombinant antibody-based molecule and methods of treating multiple myeloma or lymphoma in a patient using the recombinant antibody-based molecules or the nucleic acid molecules.
    Type: Grant
    Filed: February 25, 2004
    Date of Patent: January 13, 2015
    Assignee: Vaccibody AS
    Inventors: Bjarne Bogen, Agnete Fredriksen Brunsvik, Inger Sandlie
  • Modified antibody
    Publication number: 20040253238
    Abstract: Recombinant antibody-based molecules that trigger both T-cell and B-cell immune responses are disclosed. The recombinant molecules are comprised by at least one targeting unit and at least one antigenic unit connected through a dimerization motif. Also disclosed are nucleic acid molecules encoding the recombinant antibody-based molecule and methods of treating multiple myeloma or lymphoma in a patient using the recombinant antibody-based molecules or the nucleic acid molecules.
    Type: Application
    Filed: February 25, 2004
    Publication date: December 16, 2004
    Inventors: Bjarne Bogen, Agnete Fredriksen Brunsvik, Inger Sandlie